Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:atccode |
L04 AC02
|
| gptkbp:bioavailability |
~95%
|
| gptkbp:casnumber |
144460-73-1
|
| gptkbp:chemical_formula |
C14 H18 N4 O5 S
|
| gptkbp:class |
interleukin inhibitors
|
| gptkbp:clinical_trial |
Phase III trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kineret
|
| gptkbp:ingredients |
anakinra
|
| gptkbp:legal_status |
prescription only
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:marketed_as |
gptkb:Kineret
|
| gptkbp:mechanism_of_action |
IL-1 receptor antagonist
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:side_effect |
headache
nausea increased risk of infections injection site reactions |
| gptkbp:used_for |
gptkb:juvenile_idiopathic_arthritis
gptkb:rheumatoid_arthritis gout |
| gptkbp:weight |
334.38 g/mol
|
| gptkbp:bfsParent |
gptkb:Genentech
|
| gptkbp:bfsLayer |
4
|